May 21, 2025

Thailand Sets New Benchmark for Newborn Screening

Long-read whole genome sequencing boosts population-scale health strategy

The Pathologist

May 19, 2025

Zyrtec and Xyzal: FDA Issues Withdrawal Syndrome Warning

A new safety alert highlights the potential for severe itch following discontinuation of long-term cetirizine and levocetirizine use.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 16, 2025

CNGB3 Variant Testing Clarifies Genetic Disease Risk

Researchers found that 16 out of 21 CNGB3 gene variants altered RNA splicing, allowing clearer classification of genetic mutations linked to achromatopsia.

Conexiant

May 15, 2025

FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma

The FDA has approved a HIF-2α inhibitor for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). 

The ASCO Post

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

Who Is at Risk for LSCD?

Discover the vital role of limbal stem cells in maintaining ocular surface health and the challenges associated with limbal stem cell deficiency.

Contact Lens Spectrum

May 01, 2025

Health Care Faces New Immigration Reality

Health care facilities face new challenges as sensitive locations policy protecting them from immigration enforcement was rescinded in January 2025, requiring new protocols for patient protection.

Conexiant

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant